Robeco Institutional Asset Management B.V. Sells 160,519 Shares of Insulet Corporation $PODD

Key Points

• Robeco Institutional Asset Management cut its Insulet stake by 93% in the third quarter, selling 160,519 shares and retaining 12,010 shares valued at approximately $1.57 million.
• Insulet reported stronger-than-expected quarterly results, with earnings of $1.66 per share and revenue of $801.7 million, up 23.5% year over year.
• Analyst sentiment is mixed: Insulet has a consensus “Hold” rating and an average price target of $186.68, while several firms recently lowered their targets.

Robeco Institutional Asset Management B.V. lessened its holdings in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 93.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,010 shares of the medical instruments supplier's stock after selling 160,519 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Insulet were worth $1,567,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. State of Wyoming lifted its stake in Insulet by 34.6% in the 1st quarter. State of Wyoming now owns 284 shares of the medical instruments supplier's stock worth $60,000 after purchasing an additional 73 shares in the last quarter. Optas LLC boosted its holdings in shares of Insulet by 8.8% during the 1st quarter. Optas LLC now owns 1,059 shares of the medical instruments supplier's stock worth $222,000 after purchasing an additional 86 shares during the last quarter. American Trust boosted its holdings in shares of Insulet by 8.6% during the 1st quarter. American Trust now owns 1,180 shares of the medical instruments supplier's stock worth $248,000 after purchasing an additional 93 shares during the last quarter. Basecamp Wealth Advisors LLC grew its position in shares of Insulet by 48.3% in the first quarter. Basecamp Wealth Advisors LLC now owns 313 shares of the medical instruments supplier's stock valued at $66,000 after purchasing an additional 102 shares in the last quarter. Finally, Elevation Wealth Partners LLC grew its position in shares of Insulet by 115.6% in the third quarter. Elevation Wealth Partners LLC now owns 194 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 104 shares in the last quarter.

Insulet Stock Up 0.2%

Insulet stock opened at $149.26 on Tuesday. Insulet Corporation has a fifty-two week low of $126.40 and a fifty-two week high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The firm has a 50 day moving average price of $140.62 and a 200 day moving average price of $182.66. The company has a market capitalization of $10.35 billion, a PE ratio of 27.90, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11.

Insulet (NASDAQ:PODD - Get Free Report) last announced its earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The company had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same quarter in the previous year, the company earned $1.17 earnings per share. The firm's quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts expect that Insulet Corporation will post 6.51 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Wells Fargo & Company downgraded Insulet from an "overweight" rating to an "equal weight" rating and reduced their price objective for the stock from $255.00 to $144.00 in a research report on Wednesday, August 5th. UBS Group dropped their target price on Insulet from $174.00 to $150.00 and set a "neutral" rating for the company in a report on Thursday, August 6th. JPMorgan Chase & Co. restated a "neutral" rating and issued a $152.00 target price (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. Citigroup raised their target price on Insulet from $165.00 to $172.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 8th. Finally, Barclays raised shares of Insulet to a "hold" rating in a research report on Wednesday, October 7th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Insulet has a consensus rating of "Hold" and an average price target of $186.68.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company's primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.